Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 03 2024
01 03 2024
Historique:
received:
26
05
2023
revised:
03
08
2023
accepted:
03
01
2024
medline:
4
3
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
ppublish
Résumé
Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P < 5 × 10-8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Sections du résumé
BACKGROUND
Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer.
METHODS
We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer.
RESULTS
Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P < 5 × 10-8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior.
CONCLUSIONS
We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies.
IMPACT
Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Identifiants
pubmed: 38180474
pii: 732525
doi: 10.1158/1055-9965.EPI-23-0613
pmc: PMC10905670
mid: NIHMS1958797
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-399Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201700012C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250905
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA063673
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA235464
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200008C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA243483
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR024574
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIEHS NIH HHS
ID : K99 ES033259
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA203654
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NIA NIH HHS
ID : DP1 AG072751
Pays : United States
Organisme : NIEHS NIH HHS
ID : R00 ES033259
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA209414
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020C00001
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200008I
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167462
Pays : United States
Informations de copyright
©2024 The Authors; Published by the American Association for Cancer Research.
Références
J Thorac Oncol. 2022 Aug;17(8):974-990
pubmed: 35500836
NPJ Precis Oncol. 2021 Feb 16;5(1):12
pubmed: 33594163
Int J Cancer. 2020 Apr 1;146(7):1862-1878
pubmed: 31696517
Cell. 2019 Jan 10;176(1-2):127-143.e24
pubmed: 30633903
J Thorac Oncol. 2019 Aug;14(8):1360-1369
pubmed: 31009812
Hum Mol Genet. 2016 Feb 1;25(3):620-9
pubmed: 26732429
Nat Genet. 2008 May;40(5):616-22
pubmed: 18385676
Nat Neurosci. 2020 Jul;23(7):809-818
pubmed: 32451486
Adv Exp Med Biol. 2016;893:43-57
pubmed: 26667338
Nat Genet. 2012 Dec;44(12):1330-5
pubmed: 23143601
Lancet Respir Med. 2019 Oct;7(10):881-891
pubmed: 31326317
Nat Genet. 2014 Jul;46(7):736-41
pubmed: 24880342
Proc Am Thorac Soc. 2008 Dec 1;5(8):811-5
pubmed: 19017734
Cancer Res. 2016 Oct 1;76(19):5768-5776
pubmed: 27488534
Chromosome Res. 2010 Dec;18(8):851-72
pubmed: 21086038
Front Genet. 2014 Jun 19;5:187
pubmed: 24995013
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1474
pubmed: 29582564
Hum Mol Genet. 2007 Jan 1;16(1):24-35
pubmed: 17158188
Cancer Res. 2000 Apr 1;60(7):1949-60
pubmed: 10766185
Genet Epidemiol. 2012 May;36(4):340-51
pubmed: 22539395
Nat Genet. 2017 Jul;49(7):1126-1132
pubmed: 28604730
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):363-379
pubmed: 28615365
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W361-7
pubmed: 24829458
Gene. 2019 May 20;697:26-34
pubmed: 30772516
Cancer Discov. 2011 Oct;1(5):420-9
pubmed: 22586632
Nat Genet. 2022 Aug;54(8):1167-1177
pubmed: 35915169
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278
Mol Cell. 2013 Dec 12;52(5):720-33
pubmed: 24332178
J Hum Genet. 2021 Jan;66(1):11-23
pubmed: 32948841